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Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma:
a comparison of ﬂuorescence in-situ hybridization with a novel fully automated dual-colour
silver in-situ hybridization method
Aims: Ampliﬁcation of the human epidermal growth
factor receptor 2 (HER2) gene has been reported in
gastric carcinoma (GC). Accordingly, trastuzumab plus
chemotherapy has recently become the new standard
treatment for HER2-positive advanced GCs. The aim
was to compare the alleged gold standard for hybrid-
ization [ﬂuorescence in-situ hybridization (FISH)] with
a novel, fully automated brightﬁeld dual-colour silver-
enhanced in-situ hybridization (SISH) method.
Methods and results: The studies series was comprised
of 166 GC samples. Additionally, tumours with discor-
dant results obtained by FISH and SISH were analysed
by real-time quantitative polymerase chain reaction
(PCR) with the LightMix kit HER-2 ⁄ neu. Of the
samples, 17.5% and 21% were ampliﬁed by FISH and
SISH, respectively. Heterogeneity was identiﬁed in up to
52% of cases. In 96.4% of cases, FISH showed the same
results as SISH. All six discordant cases were positive by
SISH and negative by FISH. On review of the FISH
slides, all contradictory cases were polysomic and were
conﬁrmed to be negative for ampliﬁcation by real-time
PCR. Interestingly, all ratios in this latter group were
between 2.06 and 2.50, so setting the cut-off for
ampliﬁcation at ‡3 resulted in perfect concordance.
Conclusions: Dual-colour SISH represents a novel
method for the determination of HER2 status in GC.
Keywords: dual-colour hybridization, ﬂuorescence in-situ hybridization, gastric carcinoma, human epidermal
growth factor receptor 2, silver-enhanced in-situ hybridization
Abbreviations: CAP, College of American Pathologists; Ch, cisplatin plus ﬂuoropyrimidine; Ch+T, cisplatin plus
ﬂuoropyrimidine plus trastuzumab; DAPI, 4¢,6-diamino-2-phenylindole; DNP, dinitrophenol; EGFR, epidermal
Address for correspondence: F Lo ´pez-Rı ´os, MD, PhD, Laboratorio de Dianas Terapeuticas, Centro Integral Oncologico Clara Campal, Hospital
Universitario Madrid Sanchinarro, C ⁄ On ˜a, 10. 28050 Madrid, Spain.
e-mail: ﬂopezrios@hospitaldemadrid.com
E.G.-G. and C.G.-M. contributed equally to this work.
Re-use of this article is permitted in accordance with the terms and conditions set out at http://www3.interscience.wiley.com/authorresources/
onlineopen.html
  2011 Blackwell Publishing Limited.
Histopathology 2011, 59, 8–17. DOI: 10.1111/j.1365-2559.2011.03894.xgrowth factor receptor; FISH, ﬂuorescence in-situ hybridization; GC, gastric carcinoma; HER2, human epidermal
growth factor receptor 2; IHC, immunohistochemistry; ISH, brightﬁeld in-situ hybridization; PCR, polymerase chain
reaction; SISH, silver-enhanced in-situ hybridization
Introduction
In 1987, Slamon et al. described the relationship
between the ampliﬁcation of the human epidermal
growth factor receptor 2 (HER2) gene and a group of
breast carcinomas
1 for the ﬁrst time. The development,
in later years, of a speciﬁc treatment for this alteration,
the antibody trastuzumab, has been one of the greatest
successes of solid tumour oncology. Naturally, there
have been attempts to reproduce this success in other
neoplasias that can also show ampliﬁcation of HER2
(carcinomas of the stomach, bladder, lung etc.).
2–4
Finally, in the year 2009, results were presented of the
ToGA trial in patients with advanced gastric carcinoma
(GC).
2
The ToGA trial was a prospective, randomized,
multicentre phase III trial conducted in 24 centres.
This study looked for HER2 expression ⁄ ampliﬁcation
in 3807 patients with GCs, and found a positivity rate
of 22% [either by ﬂuorescence in-situ hybridization
(FISH) or immunohistochemistry (IHC) 3+]. Five hun-
dred and eighty-four HER2-positive GCs were included
and randomized between cisplatin plus ﬂuoropyrimi-
dine (capecitabine) (Ch) or the same chemotherapy
plus trastuzumab (Ch+T). Patients treated with Ch+T
showed a clinically and statistically signiﬁcant
improvement in terms of overall survival (13.8 months
versus 11.1 months, hazard ratio 0.7, 95% conﬁdence
interval 0.6–0.9, P = 0.0046). Secondary endpoints of
the study were also met; thus Ch+T signiﬁcantly
improved the overall response rate and progression-
free survival, as compared with Ch alone, without any
increase in toxic effects, including cardiac events.
Therefore, Ch+T chemotherapy has become the new
standard treatment for HER2-positive advanced gastric
cancer.
2
However, since trastuzumab was ﬁrst approved for
breast cancer, there have been notable inconsistencies
in procedures for studying HER2. This ‘cancer biomar-
ker problem’ signiﬁcantly affected the speciﬁc method:
IHC, FISH or the various types of brightﬁeld in-situ
hybridization (ISH). Similarly, it affected the concor-
dance between techniques; the cut-off point and the
workﬂow algorithm although IHC has traditionally
been considered to be the primary testing modality.
5–7
The facts that the ﬁrst American Society of Clinical
Oncology ⁄ College of American Pathologists (CAP)
consensus was not published until 2007
8 and that
there is a lack of consensus among different national
guidelines (reviewed in Bilous et al.
9) undoubtedly
contributed to the problem. Further fuelling the con-
troversy was the subtle recommendation of initial FISH
in speciﬁc settings (core-needle biopsies)
10 and the
direct suggestion of ‘FISH as the primary HER2 testing
modality for women with breast cancer who are
candidates for HER2-targeted therapies’.
11 This latter
paradigm shift has remained largely unnoticed, despite
being published in a high-impact journal and the
fact that Slamon was among its authors more than
20 years after his initial discovery. The situation that
we have outlined above has recently been termed ‘the
HER2 testing conundrum’, and the result is that as
many as one in ﬁve HER2 tests give the wrong
answer.
12,13
However, it must be pointed out that the clinical
beneﬁt of trastuzumab in the ToGA trial seems to
be restricted to IHC 2+ and FISH-positive or IHC 3+
patients, in the latter situation irrespective of the FISH
status.
2
With the above controversies in mind, we sought to
compare the alleged gold standard (FISH) with a novel
fully automated brightﬁeld dual-colour approach in a
series of GC samples.
14 Our aim was to provide robust
analytical and post-analytical information in the
setting of GC to guide the clinical validation of the
different assays, as has been suggested.
15
Materials and methods
tumour samples
A randomly selected total of 166 gastric adenocarci-
nomas from several Spanish institutions were collected
for HER2 status analyses. The study was approved by a
centralized ethics committee. Before parafﬁn embed-
ding, tissues were ﬁxed in buffered formalin. We have
no data regarding how concentrated the ﬁxative was
or the duration of ﬁxation. Fifty (30.1%) were endo-
scopic biopsy specimens and 116 (69.9%) were
surgical specimens, of which 15 (9%) were distant
metastases. All cases were diagnosed according to
Lauren’s classiﬁcation:
16 86 (51.8%) intestinal type,
47 (28.3%) diffuse type and 33 (19.9%) indeterminate
type.
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Sections of tumour tissue samples 4 lm thick were
cut and placed on charged polylysine-coated slides for
analysis.
fish
HER2 copy number was investigated by FISH, using the
PathVysion HER2 DNA probe kit (Vysis, Downers
Grove, IL, USA), with the Dako Histology FISH Acces-
sory kit. For the Dako Histology kit, the manufacturer’s
instructions were modiﬁed, in order to optimize the
technique (decreased laboratory processing).
17 Sections
were incubated at 56 C overnight, deparafﬁnized in two
series of xylol, and rehydrated with an ethanol series.
Slides were pretreated with Pre-treatment Solution in a
water bath at 97 C for 10 min. Enzymatic digestion
was carried out with Ready-to-Use Pepsin for 3 min at
room temperature (endoscopic biopsies) or 6 min at
37 C (surgical specimens). After dehydration with a
graded ethanol series, 10 llo fHER2 ⁄ CEP17 probe mix
was applied to each tissue section. The slides and probe
were denatured at 80 C for 5 min and hybridized at
37 C overnight in a Dako Hybridizer. On the second
day, the sections were washed with Stringent Wash
Buffer at 65 C for 10 min in a water bath. Then, the
slides were dehydrated with a graded ethanol series,
and 10 ll of ﬂuorescence mounting medium contain-
ing 4¢,6-diamino-2-phenylindole (DAPI) was applied.
dual-colour silver-enhanced in-situ
hybridization (sish)
Automated SISH was performed on a Ventana Bench-
mark XT (Ventana Medical Systems, Tucson, AZ, USA).
INFORM HER2 DNA Probe and INFORM Chromosome
17 Probe were visualized on the same slide, following
the manufacturer’s protocols, with a few variations.
Assay conditions were modiﬁed for optimal results. The
entire assay procedure (deparafﬁnization, pretreatment,
hybridization, stringency wash, signal detection and
counterstaining) was fully automated.
14 Pretreatment
was performed with Reaction Buffer and enzyme
digestion with ISH Protease 3 for 12 min. HER2 probe
was denatured at 95 C for 15 min and hybridized at
56 C for 6 h. Chromosome 17 centromere probe was
denatured at 95 C for 12 min and hybridized at 44 C
for 3 h. Stringency washes for HER2 probe were
performed at 72 C for 8 min (three steps) and incu-
bated with anti-dinitrophenol (DNP) antibody for
20 min. Then, tissue sections were incubated with
horseradish peroxidase-conjugated anti-rabbit anti-
body for 16 min. The silver signal for HER2 was
revealed by sequential silver reactions (Silver C incu-
bation time, 4 min). For chromosomal 17 centromere
probe, three stringency washes were performed at 59 C
for 8 min. Then, tissue sections were incubated with
anti-DNP antibody for 20 min and with alkaline
phosphatase-conjugated antibody for 12 min. The
signal of the centromere was visualized with the Red
ISH Naphthol reaction for 4 min. The tissues were
counterstained with Hematoxylin II for 8 min and
Bluing Reagent for 4 min. The slides were covered with
Cytoseal mounting medium. Some of the slides had to
be stained twice. We were not able to identify the cause
of these failures, which other authors have also
experienced.
18
real-time polymerase chain reaction (pcr)
Although FISH is still considered to be the gold
standard for HER2 ampliﬁcation in the clinical setting,
we sought to study our discordant cases (see below) by
a third technique.
19 Real-time quantitative PCR was
performed with the LightMix kit HER-2 ⁄ neu (Roche
Diagnostics, Indianapolis, IN, USA). A 101-bp fragment
of HER2 and a 119-bp fragment of the RPL23 reference
gene, both localized on chromosome 17q21, were
ampliﬁed according to the manufacturer’s instructions.
Simultaneous quantiﬁcation of HER2 and of the
reference gene was accomplished by using two different
LightCycler hybridization probes (LightCycler Red 640
and LightCycler Red 670, respectively), enabling dual-
colour detection in a single test tube. A colour
compensation ﬁle generated with the Roche Diagnos-
tics LightCycler Multicolour Compensation Set was
used to correct the ﬂuorescence in the duplex reaction.
DNA was extracted from formalin-ﬁxed parafﬁn-embed-
ded tumour tissue with a previously described proto-
col,
20 and subsequently ampliﬁed in triplicate with a
LightCycler 480 real-time PCR instrument (Roche
Diagnostics). In each PCR experiment, DNA extracted
from tumours with known HER2 ampliﬁcation status
(tumours classiﬁed as ampliﬁed or non-ampliﬁed by
both FISH and SISH) was included as a positive control:
three samples without ampliﬁcation and three samples
with ampliﬁcation. Moreover, each PCR experiment
included a non-template control and standards (from
10
1 to 10
6 equivalents per reaction of HER2 DNA and
of reference DNA) supplied with the kit. These stan-
dards allow the generation of standard curves for both
products to determine the linear range of both PCR
reactions and to estimate the quantity of the target
sequence in unknown samples. Brieﬂy, for each reac-
tion, 2 ll of LightCycler HER2 mix, 2 ll of LightCycler
10 E Garcı ´a-Garcı ´a et al.
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mix and 1 ll of PCR-grade water were combined. Five
microlitres of DNA (for samples and standards) or PCR-
grade water (for negative control) was added, to give a
total volume of 20 ll. PCR was performed as follows:
after an initial 10 min denaturation of DNA at 95 C,
45 ampliﬁcation cycles were performed. Each cycle
consisted of denaturation at 95 C for 10 s, annealing
at 60 C for 10 s, and extension at 72 C for 10 s. The
ﬂuorescence signals were measured after each anneal-
ing step.
post-analytical phase (interpretation)
The slides were analysed by two observers. All of the
preparation was previously evaluated (·10 and ·40
objectives in the case of SISH, and ·100 objective in the
case of FISH) to identify areas for scoring and to avoid
bias resulting from tumour heterogeneity.
For FISH, 20 nuclei were scored from two different
areas, using an epiﬂuorescence microscope (Olympus
BX61) equipped with a DAPI ⁄ Spectrum Orange ⁄ Spec-
trum Green double-ﬁlter set, using a · 100 oil immer-
sion objective lens. The scoring of SISH was similarly
conducted with the use of a brightﬁeld microscope
(Olympus BX41) with a · 40 objective. HER2 ampli-
ﬁcation was considered to be positive when the ISH
ratio was ‡2, and negative when the ISH ratio was <2.
Chromosome 17 polysomy was deﬁned as ‡3 CEP17
signals on average per cell.
21 Ampliﬁcation patterns in
clusters versus double minutes were considered accord-
ing to published criteria.
22
For data analysis in the real-time assay, the
LightCycler 480 Relative Quantiﬁcation software (ver-
sion 1.5) provided by Roche Diagnostics (Indianapolis,
IN, USA) was used. The second derivative maximum
method to calculate the value of the crossing point for
target and reference genes of each sample was used.
The HER2 copy number was calculated automatically
as the ratio between HER2 and the reference gene.
The ratio HER2 ⁄ reference for each sample was
normalized to one of the non-ampliﬁed tumours
(determined either by FISH or SISH) included as
positive controls in the PCR experiment. According
to the manufacturer, a ratio between HER2 and the
reference gene of <2 is regarded as negative for HER2
ampliﬁcation, whereas a ratio of ‡2 indicates ampli-
ﬁcation of HER2.
statistical analysis
The agreement between FISH and SISH was estimated
by the percentage of agreement and by kappa statistics.
A one-sample Z-test was performed in order to test the
proportion of the two histological subtypes (intestinal
versus diffuse and indeterminate).
Results
fish
FISH was successfully performed on all samples. The
quality of the hybridization was good (Figure 1); 17.5%
were ampliﬁed, 55% had double minute ampliﬁcation
and 45% had cluster ampliﬁcation. Heterogeneity
(focal ampliﬁcation) was observed in 52% of the
ampliﬁed cases. Interobserver agreement was almost
perfect. For one observer, the median of the ratios was
5.25 and the range was 13.26. For the other observer,
the median of the ratios was 5 and the range was 17.9.
HER2 ampliﬁcation was signiﬁcantly associated with
the intestinal histological subtype when compared with
the other categories of the Lauren classiﬁcation (86%
versus 14%, P < 0.0001).
dual-colour sish
SISH was successfully performed on all samples. The
quality of the hybridization was good (Figure 2); 21%
were ampliﬁed, 34% had double minute ampliﬁca-
tion, 46% had cluster ampliﬁcation and 20% had a
mixed ampliﬁcation pattern. Heterogeneity (focal
ampliﬁcation) was observed in 29% of the ampliﬁed
cases. Interobserver agreement was almost perfect.
For one observer, the median of the ratios was 5.75
and the range was 14.64. For the other observer, the
median of the ratios was 5.65 and the range was
9.01.
correlation between fish and sish
In 96.4% of cases, FISH showed the same results as
SISH. All six discordant cases were positive by SISH and
negative by FISH (sensitivity of 1, speciﬁcity of 0.956,
concordance of 0.964, j = 0.884; Table 1). Upon
review of the FISH slides, all contradictory cases were
polysomic and were conﬁrmed to be negative for
ampliﬁcation by real-time PCR (see below). Interest-
ingly, all ratios in this latter group (including those of
the two observers) were between 2.06 and 2.50, so
setting the cut-off for ampliﬁcation at ‡3 would result
in perfect concordance (sensitivity of 1, speciﬁcity of 1,
concordance of 1, j = 1; Table 2). All of the ratios
(including those of the two observers) of the SISH
concordant cases were greater than 3 (medians of 8.1
and 6.02; ranges of 13.66 and 8.02).
HER2 gastric carcinoma 11
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Six tumours with discordant results obtained by FISH
and SISH were analysed by real-time quantitative PCR
with the LightMix kit HER-2 ⁄ neu (Roche Diagnostics),
in order to classify them as ampliﬁed or non-ampliﬁed
for HER2 (Table 3). Samples ampliﬁed by FISH and
SISH, considered as positive controls for HER2 ampli-
ﬁcation, were all found to be ampliﬁed with the
real-time quantitative approach. Similarly, samples
assessed as negative for HER2 ampliﬁcation by both
FISH and SISH gave a normalized HER2 ⁄ RPL23 ratio
of 1 (range from 0.836 to 1.0), which is below the
cut-off limit of 2 and conﬁrms the absence of
ampliﬁcation. None of the samples with discordant
results showed ampliﬁcation of HER2 by real-time
quantitative PCR. After normalization of the tar-
get ⁄ reference gene ratio for each sample, values of
<2 were found for all tumours, conﬁrming the results
obtained by FISH.
Discussion
In the present study, we have compared for the ﬁrst
time a novel, fully automated dual-colour SISH method
with FISH for the assessment of HER2 ampliﬁcation in
a large series of GC samples. There follows a discussion
of the different phases of the procedures.
A
B
C
D
Figure 1. Gastric carcinoma with HER2 ampliﬁcation. A,B, ampliﬁcation in clusters by (A) ﬂuorescence in-situ hybridization (FISH) and
(B) silver-enhanced in-situ hybridization (SISH). C,D, ampliﬁcation in a double minute pattern by (C) FISH and (D) SISH.
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ability of the pre-analytical phase in pathology labora-
tories worldwide, as long as buffered formalin is used as
the ﬁxative. In our experience as a referral laboratory
for FISH HER2 testing, only 3% are considered to be
non-informative because of pre-analytical aspects
(F. Lo ´pez-Rı ´os, unpublished data). Expanded decalciﬁ-
cation protocols even permit ISH in bone marrow
biopsy specimens (E. Garcı ´a-Garcı ´a, unpublished data).
Although the role of the new rapid ﬁxatives remains to
be determined, it must be emphasized that alcohol-
based ﬁxation is not appropriate for ISH procedures. In
the present series, in spite of the fact that samples of
different sizes (endoscopic versus surgical specimens,
etc.) and sources (community hospitals versus large
university hospitals, etc.) were studied, both methods
showed very low failure rates (data not shown). These
results are consistent with previous reports on failure
rates for epidermal growth factor receptor (EGFR) SISH
versus FISH.
23
Second, manual ISH (i.e. FISH) remains the gold
standard in this setting, and will remain so until proven
otherwise. Nevertheless, new automated ISH alterna-
tives may improve the reproducibility of the analytical
phase if the technical platforms, reagents and protocols
are fully standardized. In the past, there were two main
limitations to the widespread use of ISH techniques:
(i) FISH has traditionally been perfomed in central or
referral laboratories, with a lack of community accep-
tance or experience; and (ii) bright-ﬁeld ISH has not,
A
B
C
D
Figure 2. In-situ hybridization of HER2 in gastric carcinoma. A,B Non-ampliﬁed case by (A) ﬂuorescence in-situ hybridization (FISH) and
(B) silver-enhanced in-situ hybridization (SISH). C,D, Chromosome 17 polysomy by (C) FISH and (D) SISH.
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14,24,25
The new, fully automated, dual-colour SISH overcomes
both limitations, but appropriate training is essential
for adequate performance of the post-analytical phase
(interpretation) of the procedure. This is somewhat
easier and quicker for bright-ﬁeld ISH than for
FISH.
26,27 It is beyond the scope of this study to
establish the predictive value of the different ISH
modalities in GC patients who are candidates for
HER2-targeted therapies, but the use of automated
ISH techniques may enable rapid screening of thou-
sands of patients in order to determine the real
predictive cut-off for clinical beneﬁt (i.e. polysomy,
degree of HER2 ampliﬁcation).
Discrepancy between FISH and SISH occurred in six
of 166 cases, all of them positive for SISH (all ratios
between 2.06 and 2.50) and negative for FISH. All
discrepant cases were polysomic by FISH and negative
for HER2 ampliﬁcation by real-time PCR. These results
are consistent with previous studies reporting on both
EGFR and HER2 brightﬁeld ISH, both using single-
colour
18,27–32 and dual-colour
14,24,26,33 approaches.
However, it must pointed out that, in some series, the
brightﬁeld ISH results are ‘false’ negatives, not ‘false’
positives, and this has potential clinical conse-
Table 2. Performance of silver-enhanced in-situ hybridiza-
tion (SISH) with a cut-off ‡3
FISH
Total Positive Negative
SISH
Positive 29 0 29
Negative 0 137 137
Total 29 137 166
FISH, ﬂuorescence in-situ hybridization.
Table 3. Correlation of HER2 status studied by ﬂuorescence in-situ hybridization (FISH), silver-enhanced in-situ hybridization
(SISH) and real-time quantitative polymerase chain reaction (PCR)
Sample ID* FISH analysis SISH analysis
Real-time quantitative PCR
HER2 ⁄ RPL23 ratio Normalized ratio Status
12 Non-ampliﬁed Non-ampliﬁed 0.9272 1.0 Non-ampliﬁed
9 Non-ampliﬁed Non-ampliﬁed 0.7752 0.8361 Non-ampliﬁed
11 Non-ampliﬁed Non-ampliﬁed 0.8314 0.8967 Non-ampliﬁed
35 Ampliﬁed Ampliﬁed 18.70 20.17 Ampliﬁed
84 Ampliﬁed Ampliﬁed 12.43 13.40 Ampliﬁed
85 Ampliﬁed Ampliﬁed 1.95 2.103 Ampliﬁed
68 Non-ampliﬁed Ampliﬁed 0.3276 0.3533 Non-ampliﬁed
39 Non-ampliﬁed Ampliﬁed 0.8597 0.9271 Non-ampliﬁed
67 Non-ampliﬁed Ampliﬁed 0.8880 0.9577 Non-ampliﬁed
113 Non-ampliﬁed Ampliﬁed 0.7460 0.8045 Non-ampliﬁed
129 Non-ampliﬁed Ampliﬁed 0.5388 0.5811 Non-ampliﬁed
8 Non-ampliﬁed Ampliﬁed 0.8503 0.9171 Non-ampliﬁed
*Negative controls: samples 12, 9 and 11. Positive controls: samples 35, 84 and 85. Discordant cases: samples 68, 39, 67, 113,
129 and 8.
Table 1. Performance of silver-enhanced in-situ hybridiza-
tion (SISH) with a cut-off ‡2
FISH
Total Positive Negative
SISH
Positive 29 6 35
Negative 0 131 131
Total 29 137 166
FISH, ﬂuorescence in-situ hybridization.
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14,24,33 Interestingly, polysomy has been
reported as the major cause of response to trastuzumab
in FISH-negative breast carcinoma patients.
34 In our
series, no cases showing gene ampliﬁcation by FISH
were considered to be negative by SISH. When we
raised the SISH cut-off for ampliﬁcation (‡3), the
concordance was 100%, demonstrating that SISH is a
valid testing method for HER2 testing in GC patients
and that a higher cut-off (‡3) should be considered
even for dual-colour SISH, in order to increase the
concordance rate. It is also necessary to take into
account that polysomy may be the cause of inter-
observer differences.
29 A very recent report on a study
using a similar methodogy to the one reported herein
(fully automated SISH assay with single-colour locus
detection on two separate slides) has arrived at the
same conclusions: chromosome 17 counts are the
main source of discrepancy between SISH and FISH
ratios.
27 Another potential source of disagreement
between ISH techniques is heterogeneity.
23,24,28
Although heterogeneity occurred in up to 52% of our
ampliﬁed cases, it did not cause the discrepancies,
because, before scoring, screening of the entire slide
took place.
Another interesting aspect to consider is the concor-
dance of ratios between the different ISH techniques. In
agreement with some authors
33 and in disagreement
with others,
25,26 there seems to be, in our series, a
weak trend towards lower ratios for FISH than for
brightﬁeld ISH. This should be taken into consideration
if, in the future, the ratio has predictive value, as has
been demonstrated in the neoadjuvant setting of breast
carcinoma patients.
35 Interestingly, the HERA trial has
failed to conﬁrm that the degree of HER2 ampliﬁcation
inﬂuences the beneﬁt from adjuvant trastuzumab.
However, it is important to emphazise that central
FISH analyses were only available in 61% of the
patients randomized, and that the analyses were
performed in two different laboratories.
36 Following
that line of reasoning, in the future, large trials could
beneﬁt from the availability of robust automated
hybridization assays that allow for a rapid (<24 h),
reliable and permanent ISH technique.
An analysis of the literature on ISH in GC is
consistent with our results, although there are no data
yet on the use of dual-colour brightﬁeld ISH ap-
proaches. A recent publication reviewed this matter.
An analysis, combining this information with our
literature shows that, in 2513 samples, the mean
HER2 positivity rate was 16.5% (range 6.9–42.6%),
very similar to the results of our series.
22,34,37–39
Agreement exists that this alteration is associated with
GCs of the intestinal type, but it is controversial
whether it is homogeneous or focal.
39,40 In the present
study, HER2 ampliﬁcation was indeed more frequent in
that histological type and heterogeneous in up to 52%
of the samples. This result emphasizes the need to
screen the whole slide before scoring, a post-analytical
approach that is easier with SISH than with FISH.
The implementation of FISH in local laboratories has
fallen below the initial expectations (approximately 4%
of hospitals with <300 beds), according to a recent
CAP survey.
41 Therefore, it is likely that interpretation
of gastric HER2 SISH will be performed by pathologists
who are not familiar with FISH. SISH has three main
advantages over FISH (permanent record, brightﬁeld
post-analytical phase and fully automated analytical
phase) that are particularly relevant in gastric HER2
assessment: (i) SISH slides are easier to screen at low
power (important with heterogeneity, as mentioned
above); (ii) co-localization of ISH and IHC ﬁndings is
straightforward with brightﬁeld assays (approximately
8–13% of GCs may exhibit HER2 genetic–protein
discordances);
2 and (iii) the availability of a fully
automated SISH method that allows for rapid subgroup
analysis of the ToGA trial samples (mining of this
database is of great interest with regard to understand-
ing why patients who are IHC 0 or 1+ and FISH-
positive do not seem to beneﬁt from trastuzumab).
2
In summary, we have compared two different ISH
approaches for HER2 testing in GC. The excellent
concordance and the absence of false-negative cases
validate this novel, automated, dual-colour SISH
method. The few discrepant results with FISH were
caused by polysomy. This shortcoming may be avoided
by raising the cut-off for ampliﬁcation (‡3). Consensus
at global and national levels is urgently needed in this
setting as a framework for analytical (technical) and
post-analytical (interpretative) training.
42 The imple-
mentation of new methodology should be based on GC
data but take into serious consideration the previous
vicissitudes in the experience of breast cancer HER2
testing.
43
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